SecBot SecBot
8-K ·Filed May 12, 2026

RIGL

RIGEL PHARMACEUTICALS INC
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001034842-26-000038
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight ▲ Bullish

Rigel shares are likely to react positively to acquiring a marketed oncology asset with existing revenue. Watch for HSR clearance and sales trajectory updates in subsequent quarters. The deal adds a near-term revenue stream but carries significant upfront and milestone cash obligations.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$32.13
T+0 close · May 12, 2026 · via day close
Latest settled
+25.02%
T+60 · $40.17
Vs SPY
+20.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $32.13entry
  2. T+1 · 6mo ago 0.00%α +0.00% · $32.13
  3. T+5 · 6mo ago −11.92%α −10.76% · $28.30
  4. T+20 · 5mo ago −0.16%α +0.46% · $32.08
  5. T+60 · 3mo ago +25.02%α +20.59% · $40.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rigel Pharmaceuticals entered into a worldwide exclusive license agreement with Arvinas and Pfizer for VEPPANUTM (vepdegestrant), an FDA-approved ER+/HER2- breast cancer treatment. Rigel will pay $70M upfront, $15M on transition completion, up to $320M in milestones, plus tiered royalties, and reimburse up to $40M in development costs. The deal provides Rigel with a commercial-stage asset, representing a significant pipeline and revenue opportunity.

Key Financial Metrics

Deal Value
$70.0M
Deal Type
license

Key Facts

  • Rigel obtains exclusive worldwide license for VEPPANU (vepdegestrant), an approved ER+/HER2- breast cancer drug.
  • Upfront payment of $70 million, plus $15 million upon successful transition completion.
  • Up to $320 million in regulatory and sales milestone payments ($60M regulatory, $260M sales).
  • Tiered royalties on net sales from mid-teens to mid-twenties percentages.
  • Rigel to reimburse licensors up to $40 million for development costs related to transition activities.
  • Agreement subject to HSR antitrust waiting period.

Financial Impact

Upfront $70M cash payment (~14% of market cap) plus $15M near-term, $40M development reimbursement, and up to $320M contingent milestones over life of royalty term.

cashrevenuer&d_expensesroyalty_expense

Risk Factors

  • Execution risk in transitioning manufacturing and commercial activities from Pfizer.
  • Sales of VEPPANU may not meet thresholds to trigger milestones or cover upfront costs.
  • Potential integration challenges and dilution from future capital raises to fund payments.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001034842-26-000038
Document: 0001034842-26-000038-index.html0001034842-26-000038
Document: 0001034842-26-000038.txt0001034842-26-000038

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026